Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation

Show full item record



Permalink

http://hdl.handle.net/10138/305535

Citation

Chen , J , Verni , C C , Jouppila , A , Lassila , R & Diamond , S L 2018 , ' Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation ' , Thrombosis Research , vol. 169 , pp. 143-151 . https://doi.org/10.1016/j.thromres.2018.07.026

Title: Dual antiplatelet and anticoagulant (APAC) heparin proteoglycan mimetic with shear-dependent effects on platelet-collagen binding and thrombin generation
Author: Chen, Jason; Verni, Christopher C.; Jouppila, Annukka; Lassila, Riitta; Diamond, Scott L.
Contributor: University of Helsinki, Clinicum
University of Helsinki, Clinicum
Date: 2018-09
Language: eng
Number of pages: 9
Belongs to series: Thrombosis Research
ISSN: 0049-3848
URI: http://hdl.handle.net/10138/305535
Abstract: Heparin proteoglycans (HEP-PGs) carry standard heparin-mediated anticoagulant properties as well as novel antiplatelet functions, a combination that may be significant for targeting multiple pathways in a single therapy. Recent work developing semisynthetic HEP-PG mimetics has shown promising results also in vivo, however flow conditions in vitro that replicate in vivo hemodynamics have not been reported. In this work, we present several assays (platelet calcium mobilization, aggregometry, microfluidic tests at venous and arterial hemodynamics) to characterize specific mechanistic effects of dual antiplatelet and anticoagulant (APAC) constructs as mimetics of HEP-PGs. Three APACs with different conjugation levels of heparin chains (CL10, CL18, HICL) were shown to decrease platelet deposition to collagen surfaces in PPACK-treated whole blood at venous shear rate (200 s(-1)). FXIIa-inhibited whole blood (CTI: corn trypsin inhibitor, 40 mu g/mL) perfused over collagen/tissue factor showed reduced both platelet and fibrin deposition when treated with APACs. IC50 values for platelet and fibrin inhibition were calculated for each molecule at venous shear rate. Increasing the shear rate to arterial flows (1000 s(-1)) and using APAC as the sole anticoagulant, resulted in a more potent antiplatelet effect of APAC, suggesting an added effect on von Willebrand Factor (vWF) function. Additionally, APAC caused an inhibition of calcium mobilization specific to thrombin and collagen stimulation and a dose-dependent reduction in collagen-mediated platelet aggregation. Understanding the sensitivity of APAC activity to shear rate, platelet signaling and procoagulant pathways is important for applications in which APAC administration may have beneficial therapeutic effects.
Subject: ANTITHROMBOTIC DRUGS
WHOLE-BLOOD
PHARMACOLOGY
COAGULATION
ACTIVATION
MECHANISMS
INHIBITORS
THERAPY
ASPIRIN
ASSAY
3121 Internal medicine
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Dual_antiplatelet_and_anticoagulant_.pdf 2.902Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record